{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:55:03Z","timestamp":1770746103655,"version":"3.49.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.3816\/ccc.2010.n.046","type":"journal-article","created":{"date-parts":[[2011,1,5]],"date-time":"2011-01-05T21:18:07Z","timestamp":1294262287000},"page":"315-318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Safety and Efficacy of Panitumumab Therapy After Progression With Cetuximab: Experience at Two Institutions"],"prefix":"10.3816","volume":"9","author":[{"given":"Muhammad Wasif","family":"Saif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Kaley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Sitki","family":"Copur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CCC.2010.n.046_bib1","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMra040958","article-title":"Systemic therapy for colorectal cancer","volume":"352","author":"Meyerhardt","year":"2005","journal-title":"N Engl J Med"},{"key":"10.3816\/CCC.2010.n.046_bib2","series-title":"New Treatment Strategies for Metastatic Colorectal Cancer","first-page":"21","article-title":"First-line treatment: approaches with cytotoxic and biologic agents","author":"Van Cutsem","year":"2008"},{"key":"10.3816\/CCC.2010.n.046_bib3","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1517\/14712598.7.6.871","article-title":"The developing trend of monoclonal antibodies in the treatment of colorectal cancer","volume":"7","author":"Elfiky","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"10.3816\/CCC.2010.n.046_bib4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1053\/j.seminoncol.2006.04.003","article-title":"Epidermal growth factor receptor targeting in cancer","volume":"33","author":"Mendelsohn","year":"2006","journal-title":"Semin Oncol"},{"key":"10.3816\/CCC.2010.n.046_bib5","first-page":"118","article-title":"Role of panitumumab in the management of metastatic colorectal cancer","volume":"6","author":"Saif","year":"2006","journal-title":"Clin Colorectal Cancer"},{"key":"10.3816\/CCC.2010.n.046_bib6","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2010.n.046_bib7","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2010.n.046_bib8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.3816\/CCC.2010.n.046_bib9","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3816\/CCC.2010.n.046_bib10","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","article-title":"Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer","volume":"27","author":"Bokemeyer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2010.n.046_bib11","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"key":"10.3816\/CCC.2010.n.046_bib12","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1592\/phco.28.6.742","article-title":"Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer","volume":"28","author":"Jean","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"suppl 1","key":"10.3816\/CCC.2010.n.046_bib13","first-page":"18","article-title":"Management of infusion reactions in clinical trials and beyond: the US and EU perspectives","volume":"23","author":"Cmelak","year":"2009","journal-title":"Oncology"},{"key":"10.3816\/CCC.2010.n.046_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/CAD.0b013e32800feecb","article-title":"Panitumumab the first fully human monoclonal antibody: from the bench to the clinic","volume":"18","author":"Cohenuram","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.3816\/CCC.2010.n.046_bib15","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00280-008-0831-6","article-title":"Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature","volume":"63","author":"Saif","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CCC.2010.n.046_bib16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrclinonc.2009.111","article-title":"Implications for KRAS status and EGFR-targeted therapies in metastatic CRC","volume":"6","author":"Normanno","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.3816\/CCC.2010.n.046_bib17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10637-009-9268-y","article-title":"Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience","volume":"28","author":"Power","year":"2010","journal-title":"Invest New Drugs"},{"issue":"15 suppl","key":"10.3816\/CCC.2010.n.046_bib18","first-page":"630s","article-title":"Panitumumab and cetuximab epitope mapping and in vitro activity","volume":"26","author":"Freeman","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2010.n.046_bib19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ccr.2008.03.010","article-title":"A molecular view of anti-erbB monoclonal antibody therapy","volume":"13","author":"Leahy","year":"2008","journal-title":"Cancer Cell"},{"key":"10.3816\/CCC.2010.n.046_bib20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ccr.2008.02.019","article-title":"Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization","volume":"13","author":"Schmiedel","year":"2008","journal-title":"Cancer Cell"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811700202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811700202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:56:49Z","timestamp":1761519409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002811700202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S1533002811700202"],"URL":"https:\/\/doi.org\/10.3816\/ccc.2010.n.046","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Panitumumab Therapy After Progression With Cetuximab: Experience at Two Institutions","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CCC.2010.n.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}